TY - JOUR
T1 - Combination of Gold Nanoparticles with Carnitine Attenuates Brain Damage in an Obesity Animal Model
AU - da Silva, Larissa Espindola
AU - Abel, Jessica Silva
AU - Tartari, Gisele
AU - da Silva, Mariella Reinol
AU - de Oliveira, Mariana Pacheco
AU - Vedova, Larissa Marques Dela
AU - Mendes, Talita Farias
AU - Mendes, Rayane Luiz
AU - Soares, Hevylin Jacintho
AU - Vernke, Camila Nandi
AU - Zaccaron, Rubya Pereira
AU - Lemos, Isabela Silva
AU - Petronilho, Fabricia
AU - Silveira, Paulo Cesar Lock
AU - Streck, Emilio Luiz
AU - de Ávila, Ricardo Andrez Machado
AU - de Mello, Aline Haas
AU - Rezin, Gislaine Tezza
N1 - © 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2024/9
Y1 - 2024/9
N2 - Obesity causes inflammation in the adipose tissue and can affect the central nervous system, leading to oxidative stress and mitochondrial dysfunction. Therefore, it becomes necessary to seek new therapeutic alternatives. Gold nanoparticles (GNPs) could take carnitine to the adipose tissue, thus increasing fatty acid oxidation, reducing inflammation, and, consequently, restoring brain homeostasis. The objective of this study was to investigate the effects of GNPs associated with carnitine on the neurochemical parameters of obesity-induced mice. Eighty male Swiss mice that received a normal lipid diet (control group) or a high-fat diet (obese group) for 10 weeks were used. At the end of the sixth week, the groups were divided for daily treatment with saline, GNPs (70 µg/kg), carnitine (500 mg/kg), or GNPs associated with carnitine, respectively. Body weight was monitored weekly. At the end of the tenth week, the animals were euthanized and the mesenteric fat removed and weighed; the brain structures were separated for biochemical analysis. It was found that obesity caused oxidative damage and mitochondrial dysfunction in brain structures. Treatment with GNPs isolated reduced oxidative stress in the hippocampus. Carnitine isolated decreased the accumulation of mesenteric fat and oxidative stress in the hippocampus. The combination of treatments reduced the accumulation of mesenteric fat and mitochondrial dysfunction in the striatum. Therefore, these treatments in isolation, become a promising option for the treatment of obesity.
AB - Obesity causes inflammation in the adipose tissue and can affect the central nervous system, leading to oxidative stress and mitochondrial dysfunction. Therefore, it becomes necessary to seek new therapeutic alternatives. Gold nanoparticles (GNPs) could take carnitine to the adipose tissue, thus increasing fatty acid oxidation, reducing inflammation, and, consequently, restoring brain homeostasis. The objective of this study was to investigate the effects of GNPs associated with carnitine on the neurochemical parameters of obesity-induced mice. Eighty male Swiss mice that received a normal lipid diet (control group) or a high-fat diet (obese group) for 10 weeks were used. At the end of the sixth week, the groups were divided for daily treatment with saline, GNPs (70 µg/kg), carnitine (500 mg/kg), or GNPs associated with carnitine, respectively. Body weight was monitored weekly. At the end of the tenth week, the animals were euthanized and the mesenteric fat removed and weighed; the brain structures were separated for biochemical analysis. It was found that obesity caused oxidative damage and mitochondrial dysfunction in brain structures. Treatment with GNPs isolated reduced oxidative stress in the hippocampus. Carnitine isolated decreased the accumulation of mesenteric fat and oxidative stress in the hippocampus. The combination of treatments reduced the accumulation of mesenteric fat and mitochondrial dysfunction in the striatum. Therefore, these treatments in isolation, become a promising option for the treatment of obesity.
KW - Animals
KW - Carnitine/pharmacology
KW - Metal Nanoparticles
KW - Gold/pharmacology
KW - Male
KW - Obesity/drug therapy
KW - Mice
KW - Disease Models, Animal
KW - Oxidative Stress/drug effects
KW - Brain/drug effects
KW - Diet, High-Fat
KW - Mitochondria/drug effects
KW - Brain Injuries/drug therapy
KW - Body Weight/drug effects
U2 - 10.1007/s12035-024-03984-1
DO - 10.1007/s12035-024-03984-1
M3 - Article
C2 - 38296901
SN - 0893-7648
VL - 61
SP - 6366
EP - 6382
JO - Molecular Neurobiology
JF - Molecular Neurobiology
IS - 9
ER -